A substantial shareholding can represent years of work and a significant part of its owner’s wealth. When that owner needs capital, financing against the shares is one option to assess alongside an outright sale.
A non-recourse stock loan provides financing against listed shares, with the lender’s recovery of the loan limited to the agreed collateral. For the borrower, the central benefit is a defined boundary around repayment exposure. The scope of that protection, and the rights attached to the shares during the term, are set out in the transaction documents.
Silo’s approach combines privately negotiated terms with prefunding through its designated broker-dealer. The borrower can verify that capital for the approved advance is in place before depositing the corresponding collateral.
What non-recourse means
Under a fully non-recourse repayment provision, the collateral is the lender’s source of recovery if the loan is not repaid. If its realized value falls short of the debt, the lender cannot pursue the borrower’s other assets for that loan shortfall, within the scope of the agreed limitation.
The borrower and their advisers should confirm how that limitation operates across the complete agreement, including any express exceptions or separate obligations.
Non-recourse does not protect the shares against a fall in value or prevent the loss of collateral following an event that permits enforcement. The documents establish the relevant triggers, any opportunity to remedy a shortfall, and the consequences if the conditions are not met.
What happens to the shareholding
Financing can be structured through a pledge or a transfer of title. The arrangement determines who owns the shares, who can give instructions over them and what must be returned when the borrower satisfies the repayment conditions.
Economic exposure also needs to be understood separately from legal ownership. Treatment of dividends, voting rights, corporate actions and share-price movements should be clear. A borrower should know whether the return obligation concerns the pledged securities or equivalent securities, and the conditions and timing of that return.
The lender’s permitted use of collateral during the term is another part of the agreement. Where transfer, lending or reuse is permitted, those rights form part of the financing arrangement and should be reviewed before proceeding.
How to compare the alternatives
Brokerage margin loans and bank securities-backed credit can also provide liquidity against investments. A brokerage margin borrower may remain liable for a shortfall, and the broker may have rights to liquidate without advance notice. A useful comparison considers recourse, collateral rights, costs, repayment flexibility and termination conditions, rather than the product name alone.
Assessing a proposed facility
The most attractive headline rate may not produce the most suitable financing. A shareholder should assess the proposed arrangement against the purpose of the borrowing and the importance of the shareholding.
The amount and funding conditions
Understand the amount proposed, the approvals still required and the conditions governing any advance. An indicative maximum is not itself a commitment to provide that amount.
The cost and repayment obligations
Consider interest, fees, their payment dates and any restrictions or charges on early repayment. The borrower should have a clear view of how the financing will be repaid and what happens if circumstances change.
The treatment of collateral
Review permitted collateral use, valuation provisions, default triggers and any applicable cure rights together with the non-recourse provision. The arrangements for return on repayment deserve the same attention as the arrangements for funding.
Silo’s approach
Silo lends as principal. For an approved advance, capital is placed in an account opened in the borrower’s name at the designated licensed broker-dealer before the corresponding collateral is deposited. Funds are released when the agreed settlement conditions are met.
The transaction documents define the parties’ rights and obligations, including permitted collateral use, the scope of non-recourse protection and the conditions for repayment and return. Full drafts are provided to the borrower’s counsel before signing.
Frequently asked questions
Is a non-recourse stock loan the same as a margin loan?
No. A brokerage margin borrower may remain liable for a shortfall, and the broker may have rights to liquidate without advance notice. In a non-recourse stock loan the lender’s recovery of the loan is limited to the agreed collateral, within the scope of the transaction documents. Compare recourse, collateral rights, costs, repayment flexibility and termination conditions rather than the product name alone.
Does non-recourse mean I cannot lose my shares?
No. Non-recourse describes the lender’s recovery rights if the loan is not repaid. It does not protect the shares against a fall in value or prevent the loss of collateral following an event that permits enforcement. The documents set the triggers, any opportunity to remedy a shortfall, and the consequences.
What should I understand about the funding before my shares move?
The amount proposed, the approvals still required and the conditions governing any advance; an indicative maximum is not a commitment to provide that amount. At Silo, capital for an approved advance is placed in an account in the borrower’s name at the designated licensed broker-dealer before the corresponding collateral is deposited, and funds are released when the agreed settlement conditions are met.
Discuss a proposed facility
An initial discussion begins with the issuer, exchange, size of the shareholding and financing objective. Silo assesses each proposal individually, with funding subject to underwriting, lender approval and the definitive agreements.
This material is provided for informational purposes only. Nothing herein constitutes investment, legal, tax, securities, accounting or regulatory advice, an offer to lend or provide financing, a solicitation, a recommendation, or a commitment to enter into any transaction. Securities-backed financing involves risk, including loss of collateral. Access may be restricted by jurisdiction or residency. Any potential facility remains subject to Silo’s review, diligence, approval, jurisdictional analysis, compliance review and definitive documentation. Readers should consult their own professional advisers.